NASDAQ:SLNO

Soleno Therapeutics - SLNO Stock Forecast, Price & News

$1.72

-0.07 (-3.91%)

(As of 10/5/2022 05:29 PM ET)

Add

Compare

Today's Range: $1.70
▼
$1.83
50-Day Range: $1.63
▼
$28.80
52-Week Range: $1.60
▼
$13.50

Volume: 37,525 shs
Average Volume: 66,701 shs
Market Capitalization: $13.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Soleno Therapeutics MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.92
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.05) to ($2.10) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

255th out of 1,072 stocks

Electromedical Equipment Industry

3rd out of 23 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Soleno Therapeutics.

3.0

Short Interest

Percentage of Shares Shorted
1.25% of the float of Soleno Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Soleno Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Soleno Therapeutics has recently increased by 21.59%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Soleno Therapeutics does not currently pay a dividend.
Dividend Growth
Soleno Therapeutics does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Soleno Therapeutics has received a 70.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for genetic diseases" and "Basic medical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Soleno Therapeutics is -0.92.

3.5

News and Social Media Coverage

News Sentiment
Soleno Therapeutics has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Soleno Therapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 8 people have searched for SLNO on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.
MarketBeat Follows
3 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Soleno Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.80% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
60.89% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Soleno Therapeutics are expected to grow in the coming year, from ($4.05) to ($2.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Soleno Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Soleno Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Soleno Therapeutics has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Soleno Therapeutics (NASDAQ:SLNO) Stock

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLNO Stock News Headlines

October 3, 2022 | finance.yahoo.com

Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

September 22, 2022 | finance.yahoo.com

Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug

September 7, 2022 | finance.yahoo.com

Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds

September 6, 2022 | finance.yahoo.com

Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

August 21, 2022 | reuters.com

Soleno Therapeutics Inc

July 20, 2022 | finance.yahoo.com

Soleno Shares Surge On Regulatory Update For Its Prader-Willi Syndrome Hopeful

July 20, 2022 | finance.yahoo.com

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

July 11, 2022 | finance.yahoo.com

Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference

July 6, 2022 | finance.yahoo.com

4 Small Stocks to Bet on in an Upbeat Drugs Industry

June 14, 2022 | finance.yahoo.com

Why Soleno Therapeutics Shares Are Surging Today

June 13, 2022 | seekingalpha.com

Soleno Therapeutics surges on positive data from Prader-Willi syndrome treatment

June 13, 2022 | finance.yahoo.com

Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS

June 7, 2022 | finance.yahoo.com

Soleno Therapeutics Announces Presentations at ENDO 2022

May 19, 2022 | finance.yahoo.com

Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology

May 17, 2022 | finance.yahoo.com

Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

May 2, 2022 | finance.yahoo.com

Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome

April 13, 2022 | finance.yahoo.com

High school seniors saw a problem — so they started a biotech company

April 11, 2022 | finance.yahoo.com

How Covid stymied a Peninsula company's drug aimed at calming insatiable appetites

April 1, 2022 | finance.yahoo.com

Soleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering

April 1, 2022 | nasdaq.com

TRVN To Report Data In Mid-year, TSHA Trims Workforce, FDA Decision On SPRO's NDA To Be Delayed?

March 31, 2022 | finance.yahoo.com

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

March 29, 2022 | seekingalpha.com

Soleno Therapeutics stock slumps on pricing ~$15M stock offering

March 28, 2022 | seekingalpha.com

Soleno Therapeutics stock slides on proposed equity offering

March 28, 2022 | finance.yahoo.com

Soleno Therapeutics Announces Proposed Underwritten Public Offering

March 27, 2022 | finance.yahoo.com

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLNO Company Calendar

Last Earnings: 8/10/2022
Today: 10/06/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SLNO
CUSIP: N/A
CIK: 1484565
Web: www.soleno.life
Phone: (650) 213-8444
Fax: 650-213-8383
Employees: 17
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($4.0480)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,910,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -126.21%
Return on Assets: -67.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.43
Quick Ratio: 3.43

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.34 per share
Price / Book: 0.51

Miscellaneous

Outstanding Shares: 8,110,000
Free Float: 5,771,000
Market Cap: $13.95 million
Optionable: Not Optionable
Beta: 0.42

Key Executives

Dr. Anish Bhatnagar M.D. (Age 52)
Pres, CEO, COO & Director
Comp: $618.7k

Mr. James H. MacKaness (Age 58)
Chief Financial Officer
Comp: $392k

Ms. Kristen Yen M.S. (Age 53)
VP of Clinical Operations
Comp: $317.19k

Ms. Patricia C. Hirano (Age 56)
VP of Regulatory Affairs
Comp: $343.35k

Mr. Anthony Wondka (Age 60)
Sr. VP & GM

Dr. Neil M. Cowen M.B.A.
Ph.D., MBA, Sr. VP of Drug Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SLNO Stock - Frequently Asked Questions

How have SLNO shares performed in 2022?: Soleno Therapeutics' stock was trading at $6.15 on January 1st, 2022. Since then, SLNO shares have decreased by 72.0% and is now trading at $1.72.
View the best growth stocks for 2022 here.
When is Soleno Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our SLNO earnings forecast.
How were Soleno Therapeutics' earnings last quarter?: Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its quarterly earnings data on Wednesday, August, 10th. The company reported ($0.90) earnings per share for the quarter, topping analysts' consensus estimates of ($1.05) by $0.15.
When did Soleno Therapeutics' stock split?: Soleno Therapeutics shares reverse split on the morning of Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Soleno Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).
What is Soleno Therapeutics' stock symbol?: Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."
How do I buy shares of Soleno Therapeutics?: Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Soleno Therapeutics' stock price today?: One share of SLNO stock can currently be purchased for approximately $1.72.
How much money does Soleno Therapeutics make?: Soleno Therapeutics (NASDAQ:SLNO) has a market capitalization of $13.94 million. The company earns $-30,910,000.00 in net income (profit) each year or ($4.0480) on an earnings per share basis.
How can I contact Soleno Therapeutics?: Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The official website for the company is www.soleno.life. The company can be reached via phone at (650) 213-8444, via email at ir@soleno.life, or via fax at 650-213-8383.

This page (NASDAQ:SLNO) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Soleno Therapeutics - SLNO Stock Forecast, Price & News

Soleno Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows